Nearly three months after Genaera Corp. said it planned to divest noncore assets, the company halted ongoing Phase II programs in cystic fibrosis and prostate cancer to conserve cash for its early stage obesity drug, trodusquemine. (BioWorld Today)

Avanir Pharmaceuticals Inc. expects to pull in up to $54 million from the sale of antipsychotic drug FazaClo, a year after acquiring the drug in anticipation of an FDA nod for Zenvia in involuntary emotional expression disorder, to move Zenvia toward the finish line in IEED and diabetic neuropathy. (BioWorld Today)